Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Growth Paris  >  VALBIOTIS    ALVAL   FR0013254851

VALBIOTIS

(ALVAL)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Euronext Growth Paris
11/24/2020 11/25/2020 11/26/2020 11/27/2020 11/30/2020 Date
6(c) 6(c) 6.04(c) 6.06(c) 5.94 Last
18 734 6 617 11 650 8 711 13 070 Volume
+1.69% 0.00% +0.67% +0.33% -1.98% Change
More quotes
Financials
Sales 2020 10,1 M 12,0 M 12,0 M
Net income 2020 -2,50 M -2,98 M -2,98 M
Net cash position 2020 14,8 M 17,6 M 17,6 M
P/E ratio 2020 -17,5x
Yield 2020 -
Sales 2021 2,90 M 3,46 M 3,46 M
Net income 2021 -12,0 M -14,3 M -14,3 M
Net Debt 2021 2,20 M 2,62 M 2,62 M
P/E ratio 2021 -3,79x
Yield 2021 -
Capitalization 45,5 M 54,4 M 54,2 M
EV / Sales 2020 3,04x
EV / Sales 2021 16,4x
Nbr of Employees 36
Free-Float 86,6%
More Financials
Company
VALBIOTIS is a French Research & Development company committed to scientific innovation for the prevention and control of metabolic diseases.VALBIOTIS specializes in the development of innovative nutritional solutions for cardio-metabolic disease prevention and nutritional support for patients. The products are intended for food and pharmaceutical industries. Valbiotis is essentially intervening in the prevention of... 
More about the company
All news about VALBIOTIS
10/27VALBIOTIS : presents the first market data on untreated LDL-hypercholesterolemia..
PU
10/27VALBIOTIS : Investors presentation – November 2020
PU
10/27VALBIOTIS : Presents the First Market Data on Untreated LDL-hypercholesterolemia..
BU
10/05VALBIOTIS : Integrates The EnterNext© PEA-PME 150 Index From Euronext Paris
BU
09/30VALBIOTIS : publishes its 2020 half-year results and provides an update on its g..
PU
09/30VALBIOTIS : Investors presentation – October 2020
PU
09/30VALBIOTIS : Publishes Its 2020 Half-Year Results and Provides an Update on Its G..
BU
09/21VALBIOTIS : Investors presentation – September 2020
PU
09/21VALBIOTIS : Investors presentation – July 2020
PU
09/21VALBIOTIS : selected to present 3 studies on TOTUM-63 by the European Associatio..
PU
09/21VALBIOTIS : Selected to Present 3 Studies on TOTUM-63 by the European Associatio..
BU
09/14VALBIOTIS : receives US and European TOTUM-070 patent for reducing hypercholeste..
PU
09/14VALBIOTIS : Receives US and European TOTUM-070 Patent for Reducing Hypercholeste..
BU
08/13VALBIOTIS : Déclaration mensuelle du nombre d'actions et de droits de vote &ndas..
PU
08/03VALBIOTIS : Document d'enregistrement universel
PU
More news
News in other languages on VALBIOTIS
10/28Où l'on reparle de confinement et de papier toilette
10/28EN DIRECT DES MARCHES : Carrefour, LVMH, Peugeot, Eramet, Teleperformance, Micro..
10/28VALBIOTIS : präsentiert erste Marktdaten zur unbehandelten LDL-Hypercholesterinä..
10/27VALBIOTIS : présente les premières données de marché de l'hypercholestérolémie-L..
10/27VALBIOTIS : Présentations investisseurs – Novembre 2020
More news
Chart VALBIOTIS
Duration : Period :
VALBIOTIS Technical Analysis Chart | ALVAL | FR0013254851 | MarketScreener
Technical analysis trends VALBIOTIS
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 1
Average target price 14,70 €
Last Close Price 5,94 €
Spread / Highest target 147%
Spread / Average Target 147%
Spread / Lowest Target 147%
EPS Revisions
Managers
NameTitle
Sebastien M. Peltier Chief Executive Officer
Laurent Lévy Chairman-Supervisory Board
Jocelyn Pineau Chief Financial & Administrative Officer
Pascal Sirvent Chief Scientific Officer
Sébastien Bessy Member-Supervisory Board
Sector and Competitors
1st jan.Capitalization (M$)
VALBIOTIS170.54%55
GILEAD SCIENCES, INC.-7.62%75 249
VERTEX PHARMACEUTICALS3.54%58 953
REGENERON PHARMACEUTICALS36.90%54 255
WUXI APPTEC CO., LTD.56.53%37 916
BIONTECH SE224.65%26 484